Results 11 to 20 of about 914,661 (291)

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy

Journal of Translational Medicine, 2017
Background Coexistence of enhancer of zeste homolog 2 (EZH2) and BRAF gene aberrations has been described in many cancer types. In this study, we aim to explore the coexistence status of BRAF V600E mutation and the copy number variation of EZH2 and ...
Huan Yu, Meng Ma, Junya Yan, Longwen Xu, Jiayi Yu, Jie Dai, Tianxiao Xu, Huan Tang, Xiaowen Wu, Siming Li, Bin Lian, Lili Mao, Zhihong Chi, Chuanliang Cui, Jun Guo, Yan Kong   +15 more
doaj   +1 more source

Current strategies to diagnose and manage positive surgical margins and local recurrence after partial nephrectomy

Asian Journal of Urology, 2022
Objective: No standard strategy for diagnosis and management of positive surgical margin (PSM) and local recurrence after partial nephrectomy (PN) are reported in literature.
Umberto Carbonara, Daniele Amparore, Cosimo Gentile, Riccardo Bertolo, Selcuk Erdem, Alexandre Ingels, Michele Marchioni, Constantijn H.J. Muselaers, Onder Kara, Laura Marandino, Nicola Pavan, Eduard Roussel, Angela Pecoraro, Fabio Crocerossa, Giuseppe Torre, Riccardo Campi, Pasquale Ditonno   +16 more
doaj   +1 more source

Immune checkpoint inhibitors in renal cell carcinoma [PDF]

, 2017
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core   +1 more source

Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies [PDF]

, 2019
A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione (GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism for increased GSH levels is to counteract damaging ROS to sustain the
Meierhofer, David, Xiao, Yi
core   +2 more sources

Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

Journal of Translational Medicine, 2019
Background Melanoma is one of the most aggressive cancers with extremely poor prognosis, and the median survival time for stage IV patients is approximately 6 to 8 months.
Longwen Xu, Zhiyuan Cheng, Chuanliang Cui, Xiaowen Wu, Huan Yu, Jun Guo, Yan Kong   +6 more
doaj   +1 more source

Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse

Scientific Reports, 2021
Calcineurin inhibitors, such as Cyclosporin (CsA), are the mainstay of anti-rejection therapy in solid organ transplants but can paradoxically induce progressive nephropathy characterised by renal dysfunction and interstitial fibrosis.
Long T. Nguyen, Sonia Saad, Ying Shi, Rosy Wang, Angela S. Y. Chou, Anthony Gill, Yimin Yao, Wolfgang Jarolimek, Carol A. Pollock   +8 more
doaj   +1 more source

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]

, 2018
In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A., Marchetti, P., Nuti, M., Rughetti, A., Zizzari, I. G.   +4 more
core   +1 more source

Correction to: Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

Journal of Translational Medicine, 2019
Following publication of the original article [1], the authors reported errors in Figures 2, 3 and Figure 3 ‘continued’
Longwen Xu, Zhiyuan Cheng, Chuanliang Cui, Xiaowen Wu, Huan Yu, Jun Guo, Yan Kong   +6 more
doaj   +1 more source

Oncogenic microRNAs characterization in clear cell renal cell carcinoma [PDF]

, 2015
A key challenge for the improvement of clear cell renal cell carcinoma (ccRCC) management could derive from a deeper characterization of the biology of these neoplasms that could greatly improve the diagnosis, prognosis and treatment choice. The aim of
BELLISSIMO, TERESA, CARBONE, Antonio, DELLA ROCCA, Carlo, DI CARLO, ANGELINA, FAZI, Francesco, PALLESCHI, GIOVANNI, PASTORE, ANTONIO LUIGI, PETROZZA, Vincenzo, PORTA, NATALE   +8 more
core   +2 more sources

Efficacy and Safety of Vemurafenib in Acral and Mucosal Melanoma Patients with BRAF Gene Mutation

Zhongliu Fangzhi Yanjiu, 2018
Objective To explore the efficacy and safety of Vemurafenib in acral and mucosal melanoma patients with BRAF gene mutation. Methods We retrospectively analyzed the clinical data of 24 patients diagnosed as BRAF gene-mutant acral melanoma (AM) or mucosal ...
WEI Xiaoting, BAI Xue, MAO Lili, CHI Zhihong, SHENG Xi'nan, CUI Chuanliang, WANG Xuan, LIAN Bin, TANG Bixia, YAN Xieqiao, LI Siming, ZHOU Li, GUO Jun, SI Lu   +13 more
doaj   +1 more source